Genesis Therapeutics

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years,

UNC Charlotte researchers are contributing to pioneering breakthroughs in cancer therapeutics, communicable disease forecasting and prevention, optical applications for health care, and use of AI and other innovative computational tools — and more.

Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.

This new approach, powered by a specialised protein large language model, predicts the most effective protein variants while using 99% less data than traditional methods.